

Contents

1	The Windows of Susceptibility to Breast Cancer	1
1.1	Introduction.....	1
1.2	Risk Factor and Etiological Agents.....	2
1.3	The Concept of the Windows of Susceptibility to Carcinogenesis	5
1.4	The Windows of Susceptibility Apply to Human Breast Cancer.....	6
1.5	Effect of Hormones on Breast Cancer	9
1.6	Hormones as Carcinogens.....	9
1.7	Role of Breast Development and Cancer.....	10
1.8	Fertility and Breast Cancer Risk.....	12
1.9	Conclusions.....	13
	References.....	14
2	The So Called Pre-Neoplastic Lesions and Carcinoma In Situ	21
2.1	Introduction.....	21
2.2	The So Called Pre-neoplastic Lesions	21
2.2.1	Ductal Hyperplasia.....	22
2.2.2	Lobular Hyperplasia.....	25
2.2.3	Atypical Ductal and Lobular Hyperplasia	25
2.3	The Histopathology of DCIS	29
2.3.1	Comedocarcinoma	30
2.3.2	Papillary Carcinoma in Situ.....	33
2.3.3	Solid Form of DCIS	34
2.3.4	Cribriform Carcinoma In Situ.....	34
2.3.5	Micropapillary Carcinoma In Situ	37
2.3.6	Other Forms of DCIS.....	38
2.4	Lobular Carcinoma In Situ (LCIS).....	38
2.5	Differential Diagnosis	43
	References.....	43

3	The Pathobiology of the Breast Cancer Invasive Process.....	47
3.1	Introduction.....	47
3.2	Epithelial Mesenchymal Transition (EMT).....	47
3.3	A Human Breast Cancer Cell Model of EMT.....	49
3.4	Other Factors Involved in the EMT.....	71
3.5	Conclusions.....	74
	References.....	75
4	The Invasive Breast Cancer Types	79
4.1	Introduction.....	79
4.2	The Invasive Cancer Subtypes.....	79
4.2.1	Invasive Ductal Carcinoma No Otherwise Specified (NOS).....	80
4.2.2	Invasive Cribriform Carcinoma	92
4.2.3	Mucinous Carcinoma	92
4.2.4	Tubular Carcinoma	96
4.2.5	Medullary Carcinoma	96
4.2.6	Invasive Papillary Carcinoma.....	96
4.2.7	Apocrine Carcinoma.....	96
4.2.8	Juvenile (Secretory) Carcinoma.....	98
4.2.9	Carcinomas with Neuroendocrine Features.....	100
4.2.10	Metaplastic Carcinoma	100
4.2.11	Inflammatory Carcinoma	101
4.2.12	Paget’s Disease.....	102
4.2.13	Invasive Lobular Carcinoma.....	102
4.2.14	Mixed Ductal and Lobular Carcinoma	103
4.3	Microinvasive Breast Carcinoma.....	106
	References.....	107
5	The Molecular Basis of Breast Cancer Subtypes	111
5.1	Introduction.....	111
5.2	Initial Genomic Classification.....	111
5.3	Extended Classifications: Molecular Subtypes.....	112
5.4	The Molecular Taxonomic Breast Cancer International Consortium (METABRIC) Classification.....	114
5.5	Genomic Classification Based on the Normal Cell Subtype	114
	References.....	116
6	Stem Cells in Breast Cancer.....	117
6.1	Introduction.....	117
6.2	Cell Markers for Identifying the Stem Cell in the Mammary Gland	118
6.3	Estrogen Receptor as a Marker of Stem Cells in the Mammary Gland	120
6.4	MCF10F Cells Behave as a Stem Cell In Vitro	121
6.5	The MCF-10F in Estrogen Induced Carcinogenesis.....	123

- 6.6 The Evidence for the Role of Stem Cells in the Pregnancy Preventive Effect During Carcinogenesis 124
- 6.7 Isolation of the Stem Cells from the Rat Mammary Gland 126
- 6.8 Role of the Mammary Gland Stem Cell in the Prevention of Breast Cancer..... 128
- References..... 129
- 7 The Mechanisms of Breast Cancer Metastasis..... 135**
 - 7.1 Introduction..... 135
 - 7.2 Route of Metastasis..... 135
 - 7.3 The Mechanism of Metastasis 136
 - 7.4 The Lymphatic Vessels as a Path for Metastatic Dissemination..... 137
 - 7.5 The Concept of Stem Cells and Metastasis..... 139
 - 7.6 Role of Circulating Tumor Cells in Breast Cancer Metastasis 140
 - 7.7 Metastasis of Breast Cancer to Specific Sites 141
 - 7.8 Role of P53 and Metastasis..... 141
 - 7.9 Problems with the Treatment of Metastasis 142
 - References..... 143
- 8 How to Build Up Adequate Prognostic Markers in the Molecular Biology Context of Breast Cancer 149**
 - 8.1 Introduction..... 149
 - 8.2 Tumor Grading..... 150
 - 8.3 Tumor Grading and Prognosis of Breast Cancer 151
 - 8.4 Characteristics of the Primary Tumor, Such as ER Status, Tumor Size, and Histologic Grade, and Lymph Node Status at the Time of Surgery Served Significantly to Predict the Outcome of the Disease with Regard to Both Recurrence and Patient Survival..... 159
 - 8.5 ER and PR as Biomarkers of Prognosis..... 166
 - 8.6 Role of HER2 in Breast Cancer Diagnosis and Treatment 169
 - 8.7 Evaluation of KI67..... 173
 - 8.8 Molecular Profiling of Breast Cancer 174
 - 8.9 General Considerations..... 175
 - References..... 176
- 9 Preclinical Models for Studying Breast Cancer 183**
 - 9.1 Introduction..... 183
 - 9.2 Xenotransplantation 183
 - 9.2.1 Xenografts for Testing the Tumorigenicity of Chemically Transformed Cells..... 186
 - 9.2.2 The Oncogene C-HA-RAS Induces a Tumorigenic Phenotype in Human Breast Epithelial Cells..... 187
 - 9.2.3 Tumorigenicity of 17-β-Estradiol Transformed Human Breast Epithelial Cells..... 188

9.3	The Labeling of Cancer Cells for an In Vivo Imaging System.....	188
9.3.1	A Model for Triple Negative Breast Cancer.....	191
9.4	Development of XtMCF and LmMCF Cell Lines.....	192
9.4.1	Molecular Characterization of XtMCF and LmMCF Cells.....	194
9.4.2	XtMCF and LmMCF Cells Are Differed from bsMCF-luc Cells in Migration, Solid Masses Formation, and Colony Formation Capacity.....	195
9.4.3	XtMCF and LmMCF Cells Are Highly Tumorigenic and Metastatic In Vivo.....	196
9.4.4	Classification of Xenografts and Lung Metastases Formed by XtMCF and LmMCF Cells.....	198
9.4.5	XtMCF and LmMCF Cells Present CD24 ^{weak} /CD44 ⁺ /EpCAM ⁺ Cancer Stem Cells Properties, EGF-Like Domain of EpCAM Is Cleaved Off.....	199
9.4.6	Relevance of the Triple Negative Breast Cancer Model.....	202
	References.....	205
10	Biological Basis of Breast Cancer Prevention.....	211
10.1	Introduction.....	211
10.2	Pregnancy as a Physiological Process That Prevent Breast Cancer.....	211
10.3	Breast Development and Differentiation as the Biological Clue in Cancer Prevention.....	215
10.4	Basis of the Dual Effect of Late Pregnancy in the Increase Risk of Breast Cancer.....	219
10.5	Current Strategies in Breast Cancer Prevention.....	221
10.5.1	Experimental Data Supporting the New Strategy in Prevention.....	222
10.5.2	Clinical Studies Supporting the New Strategy in Prevention.....	224
10.5.3	Pregnancy and HCG Induce Permanent Genomic Imprinting or a Specific Signature of Protection.....	224
10.6	Developing a Prevention Clinical Trial Using HCG.....	225
10.7	Summary and Conclusions.....	228
	References.....	229



<http://www.springer.com/978-3-319-40813-2>

The Pathobiology of Breast Cancer

Russo, J.

2016, XIV, 235 p. 126 illus., 109 illus. in color.,

Hardcover

ISBN: 978-3-319-40813-2